Study in Adolescents With Schizophrenia or Bipolar Disorder

Exclusion Criteria

• •History of mental retardation, current comorbid autism, or current comorbid Pervasive Developmental Disorder.
• •Have DSM-IV-TR substance (except nicotine and caffeine) dependence within the past 30 days prior to randomization.
• •Been judged clinically to be at any suicidal risk.
• •History of allergic reaction or hypersensitivity to olanzapine.
• •Receiving current pharmaceutical treatment for weight management or are participating in a structured behavioral diet and/or exercise weight loss program.
• •Other antipsychotics, mood stabilizers, or anticonvulsants (for mood stabilization) used for the primary study conditions (bipolar I disorder or schizophrenia)
• •Have acute, serious, or unstable medical conditions
• •Have any illness such that death is anticipated within 1 year or intensive care unit hospitalization for the illness is anticipated within 12 months (365 days).
• •Have had one or more seizures without a clear and resolved etiology.
• •Baseline alanine aminotransferase (ALT) values greater than or equal to 2 times the upper limit of normal (ULN) of the performing laboratory or aspartate aminotransferase (AST) values greater than or equal to 2 times the ULN or total bilirubin values greater than or equal to 1.5 times the ULN at screening.
• •Have leukopenia or history of leukopenia without a clear and resolved etiology or known history of agranulocytosis (absolute neutrophil count \<500 cubic millimeter \[mm\^3\], \<0.5 GI/L, or \<0.5 10E\^3/microliters \[μL\]) during the participant's lifetime.
• •Prolactin level of \>200 nanograms per milliliter (ng/mL) \[\>200 micrograms per liter (ug/L), or \>4228 milli-International unit per liter (mIU/L)\] at screening.
• •Have QTc (Bazett's) \>450 milliseconds (males) or \>460 milliseconds (females) at screening.
• •Previously been randomized in this study and/or participated in a clinical trial of another investigational drug, including olanzapine, within 1 month (30 days) prior to screening.
• •Currently prescribed olanzapine for greater than or equal to 5 days within 1 month (30 days) prior to screening.
• •Are investigator site personnel directly affiliated with this study and/or their immediate families OR are employed by or representatives of Lilly.
• •Pregnant or nursing.
• •Have received treatment within the last 30 days with an investigational new drug that has not received regulatory approval for any indication at the time of study entry.
• •Treatment with clozapine within 14 days prior to randomization.
• •Participants who have used olanzapine (that is, oral olanzapine, intramuscular \[IM\] olanzapine, or olanzapine orally disintegrating tablets) and have had treatment withdrawn due to clinically significant and/or intolerable adverse effects, or who have exhibited a lack of efficacy/response to treatment to olanzapine including treatment resistance.